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Abstract. 
 
The generation of the paraxial skeleton re-
quires that commitment and differentiation of skeletal 
progenitors is precisely coordinated during limb out-
growth. Several signaling molecules have been identi-
ﬁed that are important in specifying the pattern of these 
skeletal primordia. Very little is known, however, about 
the mechanisms regulating the differentiation of limb 
mesenchyme into chondrocytes. Overexpression of 
RAR
 
a
 
 in transgenic animals interferes with chondro-
genesis and leads to appendicular skeletal defects 
(Cash, D.E., C.B. Bock, K. Schughart, E. Linney, and 
 
T.M. Underhill. 1997. 
 
J
 
.
 
 Cell Biol
 
. 136:445–457). Further 
analysis of these animals shows that expression of the 
transgene in chondroprogenitors maintains a prechon-
drogenic phenotype and prevents chondroblast differ-
entiation even in the presence of BMPs, which are 
known stimulators of cartilage formation. Moreover, an 
RAR antagonist accelerates chondroblast differentia-
tion as demonstrated by the emergence of collagen type 
II–expressing cells much earlier than in control or 
BMP-treated cultures. Addition of Noggin to limb mes-
enchyme cultures inhibits cartilage formation and the 
appearance of precartilaginous condensations. In con-
trast, abrogation of retinoid signaling is sufﬁcient to in-
duce the expression of the chondroblastic phenotype in 
the presence of Noggin. These ﬁndings show that BMP 
and RAR-signaling pathways appear to operate inde-
pendently to coordinate skeletal development, and that 
retinoid signaling can function in a BMP-independent 
manner to induce cartilage formation. Thus, retinoid 
signaling appears to play a novel and unexpected role 
in skeletogenesis by regulating the emergence of chon-
droblasts from skeletal progenitors.
Key words: retinoic acid • chondrogenesis • bone 
morphogenetic proteins • limb development • Noggin
 
Introduction
 
Patterning of the vertebrate limb bud relies on the cooper-
ative action of several signaling centers. Signals have been
identified that emanate from the apical ectodermal ridge,
dorsal ectoderm and a region within the distal posterior
margin termed the zone of polarizing activity (see Johnson
and Tabin, 1997; Tickle and Eichele, 1994, and references
therein). The mechanism by which these patterning cues
influence mesenchyme commitment is thought to occur
within the progress zone. Cells within the progress zone
receive signals from all three signaling centers, integrating
them into a positional identity that is translated into a cell
identity. With respect to skeletal formation, these signals
culminate in the commitment of mesenchymal cells to the
chondrocytic lineage.
Bones within the limb are formed from a cartilage pre-
cursor that forms from condensed mesoderm. These con-
densations represent the earliest stages of limb patterning
and are considered to be the forebears of the mature limb
bones (Ede, 1983). After condensation, the mesodermal
cells in the interior of each condensation differentiate into
chondrocytes. This differentiation occurs in concert with
limb outgrowth, such that proximal mesenchymal cells
(close to the body wall) that are fated to become chondro-
cytes differentiate before more distal cells. The spatiotem-
poral regulation of mesenchyme differentiation into chon-
drocytes is a crucial step in endochondral bone formation
in that it preserves the pattern of the bone primordia es-
tablished earlier in limb development and provides a suit-
able matrix for subsequent ossification. Despite the impor-
tance of this stage in skeletal development, mechanisms
that control mesenchyme differentiation into chondro-
cytes are poorly understood.
During limb outgrowth, signals that promote as well as
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inhibit chondrogenesis are important determinants in limb
ontogeny (Wolpert, 1990). Many molecules have been
identified that promote chondrogenesis in vivo and in
vitro. Some of these include members of the TGF-
 
b
 
 super-
family, including the bone morphogenetic proteins (BMPs)
 
1
 
,
growth differentiation factors (GDF), and TGF-
 
b
 
-1, -2, and
-3 (Kingsley, 1994; Hogan, 1996; Moses and Serra, 1996;
Wozney and Rosen, 1998). Signaling molecules that may
modulate skeletal development by inhibiting chondrogen-
esis include vitamin A and its metabolite, retinoic acid
(RA; see Underhill and Weston, 1998, and references
therein). Exposure of embryos to excess RA results in a
range of defects depending not only on the dose of RA,
but also on the timing of its administration (Shenefelt,
1972). For instance, when administered to embryonic age
(E) 11.5 to E14.5 mouse embryos, large doses of RA cause
limb defects (Kochhar, 1973; Kwasigroch and Kochhar,
1980). This period during which RA treatment has the
most dramatic effects on limb formation coincides with the
timing of chondrogenesis in the limb bud.
RA exerts most of its biological effects primarily through
receptors belonging to one of two subfamilies of the ste-
roid hormone family of nuclear receptors, the RA recep-
tors (RARs) and the retinoid X receptors (RXRs; Man-
gelsdorf et al., 1994; Chambon, 1996). Three subtypes (
 
a
 
,
 
b
 
, and 
 
g
 
) exist for both the RARs and RXRs, which are
expressed in distinct and overlapping regions during limb
development. Between E9.5 and E11.5, RAR
 
a
 
 and RAR
 
g
 
are expressed throughout the limb mesenchyme (Dolle et
al., 1989; Ruberte et al., 1990). Beyond this stage, RAR
 
a
 
is downregulated within the cartilaginous areas, while
RAR
 
g
 
 expression remains localized to these areas. RAR
 
a
 
expression becomes restricted to the interdigital region
(IDR) overlapping with RAR
 
b
 
 expression at this time,
and is also present in the perichondrium. In addition to be-
ing present in the IDR, RAR
 
b
 
 is expressed in the interior,
anterior, and posterior necrotic zones (Dolle et al., 1989;
Mendelsohn et al., 1991). While null mutants of either
RAR
 
a
 
, RAR
 
b
 
, or RAR
 
g
 
 exhibit no limb skeletal malfor-
mations (Lohnes et al., 1993; Lufkin et al., 1993; Luo et al.,
1995; Ghyselinck et al., 1997), compound homozygous null
alleles of RAR
 
a
 
 and RAR
 
g
 
 exhibit a range of severe limb
abnormalities from reductions to duplications (Lohnes et
al., 1994) demonstrating an important function for the
RARs in skeletal development.
To further explore RAR function in limb skeletogene-
sis, we used an existing transgenic line of mice that overex-
presses a weak constitutively active RAR
 
a
 
1 in the devel-
oping limb bud (Cash et al., 1997). These animals present a
number of limb skeletal abnormalities including poly-
dactyly, syndactyly, ectrodactyly, fibular deficiencies, and
tarsal and carpal fusions. Previously, we showed that
transgene-expressing cells do not differentiate into chon-
droblasts. Here we report that instead, these cells continue
to express a prechondrogenic phenotype. Addition of
BMP-2 or -4 to in vitro cultures of transgenic mesenchyme
dramatically stimulates condensation of transgene-express-
ing mesenchymal cells but fails to induce their differentia-
tion. In contrast, addition of an RAR
 
a
 
-selective antagonist
stimulates chondroblast differentiation, and is sufficient to
induce cartilage formation when BMP signaling is re-
pressed. Taken together, these results suggest that BMP
and RAR signaling play an important function in regulat-
ing both the size and shape of the skeletal primordia.
Maintenance and expansion of the prechondrogenic con-
densations is dependent upon activation of both signaling
pathways, whereas the timing of chondroblast differentia-
tion is regulated by RAR activity.
 
Materials and Methods
 
Preparation of Cultures from Limb Mesenchyme
 
Cultures were prepared from murine fore and hind limb buds of E11.25 to
E11.75 embryos (obtained from breedings of homozygous male transgenic
animals or C57Bl6F
 
1
 
/J males with C57Bl6F
 
1
 
/J females) as previously de-
scribed with the following modifications (Cash et al., 1997). After pro-
teolytic digestion, cells were filtered through a Cell Strainer (40 
 
m
 
m; Fal-
con) to obtain a single cell suspension. Culture media (40% Dulbecco’s
modified Eagle’s medium and 60% F12 supplemented with fetal bovine
serum to 10%; GIBCO BRL) was changed daily. BMP-2 or -4 (Genetics
Institutes), AGN 194301 (Allergan Pharmaceuticals), and/or purified 
 
Xe-
nopus
 
 Noggin protein was added to culture media at a concentration of 10
ng/ml, 1 
 
m
 
M, and 10 ng/ml, respectively. Addition/removal experiments
included either adding or removing supplemented media on the indicated
culture day. 24 h after culture initiation was considered day 1. To detect
transgene-expressing cells, cultures were fixed and stained as previously
described, with magenta-gal (BioSynth International Inc.) being substi-
tuted for X-gal. This was followed by alcian blue staining for cartilage-spe-
cific glycosaminoglycans (Lev and Spicer, 1964). Alcian blue staining of
magenta-gal–stained cultures turned the red precipitate to a purple color,
as a result of incubating magenta-gal–stained cells at pH 1. This double-
staining technique enables transgene-expressing cells to be localized with
respect to alcian blue–stained cartilage nodules. Images were captured us-
ing a Sony DXC-950 3CCD color video camera and analyzed using North-
ern Eclipse image analysis software (Empix Imaging, Inc.) and composite
figures were generated in CorelDraw.
 
Synthesis of Riboprobes
 
Riboprobes were synthesized in the presence of UTP-digoxigenin with the
appropriate RNA polymerase and linearized template DNA according to
the manufacturer’s directions (Roche Molecular Biochemicals). Ribo-
probe complementary to the 
 
Col II
 
 gene, was generated from BamH1 lin-
earized pBluescript containing 1.1 kb of the c-propeptide encoding region
of the 
 
Col II
 
 gene and transcribed in vitro with T7 RNA polymerase. 
 
Gli-1
 
riboprobe was transcribed from Not1 linearized pBluescript containing a
1.6-kb fragment representing most of the zinc finger domain of 
 
Gli-1
 
. A
553-bp fragment of murine 
 
Col I
 
 gene (Phillips et al., 1992) subcloned into
pKS II (Stratagene) was linearized with Xho1 and transcribed with T7
RNA polymerase. A HindIII (bp position 605) -BamH1 (bp position
1252) fragment from the mouse 
 
N-cad
 
 cDNA was subcloned into pKSII.
This construct was linearized with BamH1 and riboprobe synthesized with
T7 RNA polymerase. A 
 
Col II
 
A–specific probe was generated using RT-
PCR on limb RNA with primers (5
 
9
 
 primer, 5
 
9
 
-GTGCTGCTGACGCT-
GCTCAT and 3
 
9
 
 primer, 3
 
9
 
-ACCAGCCTTCTCGTCATACC) flanking
exon 2 of the mouse 
 
Col II
 
 gene. A product of 207 bp was subcloned into
pGEM-Teasy (Promega) and subsequently used to generate riboprobes.
Control sense riboprobes were synthesized from the aforementioned
plasmids.
 
Whole Mount In Situ Hybridization of Limb 
Mesenchyme Cultures
 
In situ hybridizations were carried out on cultures derived from limb mes-
enchyme using a technique described previously (Cash et al., 1997), with
minor modifications. After permeabilization using 10 
 
m
 
g/ml proteinase-K
in PBS supplemented with 0.05% Triton X-100, cells were post-fixed in
 
1
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4% paraformaldehyde and 2% glutaraldehyde in PBS, and hybridizations
were carried out at 60
 
8
 
C instead of 55
 
8
 
C.
 
Transient Transfection Analysis
 
The ability of AGN 194301 to inhibit all trans-RA induction of an RARE-
containing luciferase construct was performed in P19 embryonal carci-
noma cells as previously described with some modification (Underhill et al.,
1994). P19 cells were seeded at a density of 1.5 
 
3
 
 10
 
4
 
 cells/well in 6-well
plates. Cells were transfected using the calcium phosphate precipitation
method with each well receiving 3.9 
 
m
 
g DNA (1.25 
 
m
 
g pW1RAREtk-lucif,
0.33 
 
m
 
g pW1ActRAR
 
a
 
/
 
b
 
/
 
g
 
, 0.67 
 
m
 
g pW1Act
 
b
 
-galactosidase, and 1.65 
 
m
 
g
pGEM9zf(
 
2
 
)). After transfection, cells were washed and fresh media
were added that contained 1 
 
3
 
 10
 
2
 
7
 
 M all trans-RA and various amounts
of AGN 194301. 24 h later cell extracts were prepared and luciferase
and 
 
b
 
-galactosidase activity was measured. Luciferase activity was nor-
malized with 
 
b
 
-galactosidase activity to control for differences in transfec-
tion efficiency.
 
Northern Blot Analysis
 
Total limb bud RNA was isolated from pooled limb buds of wild-type and
transgenic embryos at various gestational stages using TriPure Isolation
Reagent (Roche Molecular Biochemicals). Total RNA from micromass
cultures was extracted from cells pooled from 12 wells of a 24-well plate
with TriPure Isolation Reagent. Cultures were established as described
above. RNA samples were separated by electrophoresis of 15-
 
m
 
g aliquots
on a 1% agarose-formaldehyde gel. RNA was then transferred to a Hy-
bond-N nylon membrane (Amersham Life Science) and cross-linked by
UV irradiation. Blots were prehybridized in Church’s Buffer (7% SDS,
0.5 M NaPi pH 7.2, 1 mM EDTA, and 1% BSA) at 65
 
8
 
C for at least 30
min. Radiolabeled DNA probes were synthesized by random priming
(Feinberg and Vogelstein, 1983) with the appropriate cDNA insert frag-
ments. Hybridizations were carried out overnight at 60
 
8
 
C. After hybrid-
ization, blots were washed with wash buffer (250 mM NaPi, 10% SDS)
three times for 15 min at 65
 
8
 
C and exposed to BioMax x-ray film at 
 
2
 
80
 
8
 
C
for 1–4 d.
 
Results
 
Transgene-expressing Cells Do Not Contribute to 
Cartilage Nodules
 
RAR
 
a
 
 expression is normally downregulated during chon-
droblast differentiation in vitro (Cash et al., 1997) and
in vivo (Dolle et al., 1989). The continued activity of
RAR
 
a
 
 inhibits chondroblast differentiation leading to ces-
sation of cartilage formation and to skeletal deficiencies
that are reminiscent of those observed in RA teratogenic-
ity. To examine the cell fate of transgene-expressing cells,
limb mesenchyme from the fore and hind limbs of E11.5
transgenic embryos was used to set up high density pri-
mary limb bud cultures. Under these conditions, conden-
sation and differentiation of limb mesenchyme to cartilage
mimics those events occurring in vivo (Ahrens et al.,
1977). Fig. 1 shows cartilage nodule formation at day 2 and
4 in wild-type (Fig. 1, a and b) and transgenic (Fig. 1, d and
e) fore limb cultures. Consistent with previous observa-
tions, there were fewer alcian blue–stained nodules in the
transgenic derived cultures than in the wild-type cultures.
To precisely examine the distribution of transgene-express-
ing cells in cultures, a combination of magenta-gal and al-
cian blue staining was used to stain transgene-expressing
cells and cartilage matrix, respectively. Transgene-express-
ing cells (purple stained) formed condensations but were
mostly excluded from cartilage nodules (Fig. 1 f). These
transgene-expressing condensations are still evident after
8 d in culture, suggesting that the transgene is not being
downregulated during cartilage nodule formation. Fur-
 
thermore, by day 4 in hind limb cultures there is extensive
transgene expression that almost completely precludes the
formation of cartilage nodules (Fig. 1 c). This is consistent
in vivo in that the transgene-expressing cells are not found
within the cartilaginous elements (data not shown). In the
transgenic embryos, fore limb expression of the transgene
is restricted primarily to the posterior region, thus, only a
portion of the cells in these cultures stain with magenta
gal. In the hind limb, the transgene is expressed through-
out the limb mesenchyme. This results in hind limb defects
that are more dramatic than those observed in the fore
limb (Cash et al., 1997) and coincides with an almost
complete lack of cartilage formation in hind limb cultures
(Fig. 1 c).
 
Transgene-expressing Cells Have a
Prechondrogenic Phenotype
 
Cartilage formation involves two well-described steps: (1)
condensation of mesenchymal cells, and (2) differentiation
of condensed mesenchyme to matrix-producing chondro-
cytes (Hall and Miyake, 1992). Condensed prechondro-
genic cells express 
 
Col II
 
 weakly and express 
 
N-cad
 
, 
 
Col I
 
,
and 
 
Gli-1
 
 abundantly (Walterhouse et al., 1993; Oberlender
and Tuan, 1994; Hall and Miyake, 1995; Marigo et al., 1996).
Upon differentiation of these cells, 
 
Col II
 
 expression be-
comes much stronger, whereas expression of 
 
N-cad
 
, 
 
Col I
 
,
and 
 
Gli-1
 
 is downregulated. To further characterize the
phenotype of the transgene-expressing cells, whole mount
in situ hybridization was carried out to examine the ex-
pression patterns of these genes in transgenic and wild-
type cultures. In wild-type cultures, 
 
Col II
 
 expression is
very strong and localized primarily to the core of the carti-
lage nodules with weaker expression in regions surround-
ing the nodules (Fig. 2 a). Expression of 
 
N-cad
 
, 
 
Col I
 
, and
 
Gli-1
 
 in wild-type cultures is restricted to perinodular re-
gions where condensed, undifferentiated mesenchyme is
present, and is weakly expressed in the centre of the nod-
ules (Fig. 2, c, e, and g). The expression patterns of these
genes in the wild-type cultures is consistent with their ex-
pression in vivo. In transgenic cultures, however, their ex-
pression patterns indicate that various condensations in
these cultures have been maintained instead of going on to
form cartilage nodules. In several regions, 
 
Col II 
 
was only
weakly expressed (Fig. 2 b), and instead of being downreg-
ulated, 
 
N-cad
 
, 
 
Col I,
 
 and 
 
Gli-1 
 
were all expressed through-
out the cultures (Fig. 2, d, f, and h), resembling a pattern
one would expect to see in condensations but not in carti-
lage nodules. These observations suggest that the trans-
gene-expressing cells condense but do not undergo chon-
droblast differentiation.
Comparison of the distribution of 
 
Col II
 
 expression in
transgenic and wild-type cultures suggests that a similar
number of condensations are formed in the transgenic cul-
tures as compared with wild-type cultures (Fig. 2, a and b).
Furthermore, the 
 
Col II–
 
stained regions in transgenic and
wild-type cultures were similar in size indicating that
transgene-mediated inhibition of chondroblast differentia-
tion was not a consequence of insufficient numbers of pre-
chondrogenic cells (Hall and Miyake, 1992). Moreover,
during the culture period the transgene-expressing cell ag-
gregates continued to expand in size and intensity of ma- 
The Journal of Cell Biology, Volume 148, 2000 682
 
genta-gal staining. Northern blot analysis confirmed dif-
ferential expression of 
 
Col I 
 
and 
 
Col II
 
 between the hind
limbs of wild-type and transgenic mice (Fig. 2, i and j). At
E13.5, there is a higher level of 
 
Col I
 
 expression in trans-
genic hind limbs compared with wild-type hind limbs (Fig.
2 j). In contrast, at E 14.5, 
 
Col II 
 
expression is much lower
in transgenic hind limbs in comparison to wild-type hind
limbs (Fig. 2 i). The reduced expression of 
 
Col II
 
 in trans-
genic hind limbs is likely a reflection of the decreased size
of cartilaginous elements that form and the reduced ex-
pression of the chondrogenic phenotype. Similarly, the el-
evated 
 
Col I
 
 expression in the transgenic hind limbs at
E13.5 suggests a delay in chondroblast differentiation. The
in situ hybridization results combined with results from
Northern blot analysis strongly suggest that the phenotype
displayed by transgene-expressing cells in vitro and in vivo
is that of condensed prechondrogenic cells.
 
Transgene-expressing Cells Are Refractile to
BMP-stimulated Chondroblast Differentiation
 
To further investigate the mechanism of transgene-medi-
ated inhibition of chondroblast differentiation, we exam-
ined the expression of genes known to be important in
chondrogenesis, namely the BMPs. Based on their expres-
sion in limb development and their well-defined chondro-
genic stimulatory properties, we have focused our analysis
on 
 
Bmps-2
 
 and 
 
-4
 
. One plausible explanation for the trans-
genic phenotype is either the reduced expression of 
 
Bmps
 
or overexpression of 
 
Noggin
 
 which encodes a BMP inhibi-
tor. Northern analysis using mRNA from hind limbs of
 
transgenic and wild-type animals at E 11.5, 12.5, and E
14.5 demonstrated that neither 
 
Bmp-2
 
 nor 
 
Noggin
 
 were dif-
ferentially expressed in transgenic animals in comparison
to wild-type animals (data not shown). The defect in trans-
genic limb mesenchyme, therefore, is not likely a result of
changes in expression of either of these two transcripts.
However, these results do not preclude the possibility that
transgene-expressing mesenchymal cells are unresponsive
to BMPs.
To evaluate whether transgene-expressing cells are able
to respond to BMPs, we treated transgenic and wild-type
limb mesenchymal cultures with 10 ng/ml BMP-2 and -4.
Similar to previous reports, we demonstrated that addition
of BMP-2 (Fig. 3 a) and -4 (data not shown) dramatically
increased the number of cartilage nodules in wild-type cul-
tures. BMP-2 treatment for 6 d increased the number of
cartilage nodules by 
 
z
 
125% and 
 
z
 
115% in wild-type and
transgenic fore limb cultures, respectively (Fig. 3 a). To
determine if BMP-2 completely rescues cartilage forma-
tion of transgene-expressing cells, treated cultures were
stained with magenta-gal followed by alcian blue (Fig. 3, e
and f). As observed in nontreated transgenic cultures, few
if any transgene-expressing cells were found to be present
within the alcian blue–stained cartilage nodules (Fig. 3 g).
Addition of BMP-2, however, stimulated condensation of
transgene-expressing cells as seen by magenta-gal staining
(Fig. 3, e–g), and by the expression pattern of 
 
Col II
 
 in
transgenic cultures (Fig. 3, j and k). In response to BMP-2,
condensations of transgene-expressing cells increased in
size (compare Fig. 1 e with 3 f), this is also apparent in the
 
Col II–
 
expressing condensations (Fig. 3, j and k). BMP-2
Figure 1. Transgene-expressing cells are excluded from cartilage nodules. (a and b) Wild-type fore limb cultures were fixed and stained
with alcian blue on days 2 and 4. (d and e) Transgenic fore limb cultures were stained with magental-gal on days 2 and 4, followed by al-
cian blue staining. (c) Transgenic hind limb cultures were stained with magenta-gal on day 4, followed by alcian blue staining. (f) Higher
magnification of day 4 transgenic fore limb cultures. Transgene-expressing cells condense (white arrow), but are excluded from the car-
tilage nodules (black arrow). Bar: (a, b, d, and e) 1 mm; (c and f) 0.2 mm. 
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addition stimulated the formation of 
 
Col II–
 
expressing
nodules in wild-type cultures (Fig. 3 i), while stimulating
the formation of condensations expressing 
 
Col II
 
 weakly in
transgenic cultures (Fig. 3 k). In the transgenic cultures,
condensations were observed as early as 2 d in culture and
were still evident after 6 d in culture, whereas in wild-type
cultures, there were no precartilaginous condensations vis-
ible by day 6, as almost all condensed cells had differenti-
ated by that time. Thus, although BMP-2 or -4 induces
transgene-expressing cells to form precartilaginous con-
densations they are not sufficient to overcome transgene-
mediated inhibition of chondroblast differentiation.
 
Inhibition of RARa Stimulates Chondrogenesis
We have demonstrated that continued RARa activity
inhibits the transition of prechondrogenic cells to chon-
droblasts. Consequently, we would expect that the abroga-
tion of RARa activity would stimulate chondroblast dif-
ferentiation and/or cartilage formation. RAR activity as
used herein refers to the level of RA-induced transcrip-
tional activity of the RARs. To examine the possibility that
inhibition of RARa activity stimulates cartilage forma-
tion, we treated wild-type cultures with the RARa-specific
antagonist AGN 194301 (Teng et al., 1997). At the concen-
trations of AGN 194301 (1 mM) used in these experiments,
RARa signaling was inhibited to z0.3% of 100 nM all
trans-RA–treated controls, while RARb and RARg were
inhibited to z18% and z26% of controls, respectively
(Fig. 4). Addition of 1 mM AGN 194301 to wild-type cul-
tures lead to a dramatic increase in nodule number as
compared with untreated control cultures (Fig. 5, g, j, and
m). After 8 d in culture there were 60% more nodules
in antagonist treated cultures than in untreated cultures
(Fig. 5 m). Previous studies showed that treatment of mi-
cromass cultures with anti-sense oligonucleotides to the
RARs increased cartilage nodule number (Motoyama and
Eto, 1994; Jiang et al., 1995), however, an RAR inhibitor
to all three RARs had no effect on cartilage nodule forma-
tion (Kochhar et al., 1998). Most of the chondrogenic stim-
ulatory properties of the antagonist appear to be mediated
through inhibition of RARa, however, it cannot be en-
tirely discounted that diminution of RARb or RARg sig-
naling may have contributed to these results. Nonetheless,
loss of RAR activity stimulates cartilage formation while
continued RAR activity inhibits cartilage formation.
The RARa Antagonist and BMP-2 Have Different 
Chondrogenic Stimulatory Properties
The loss of RAR activity and addition of BMP-2 and -4 both
stimulate cartilage formation. In transgenic cultures, BMP-
2/-4 stimulated condensation but not differentiation of
Figure 2. Transgene-expressing cells have a prechondrogenic
phenotype. (a–h) Whole mount in situ  hybridization of day 4
wild-type and transgenic cultures was carried out using probes
characteristic of the precartilage stage (N-cad, Col I, and Gli-1)
and chondroblast stage (col II). (a) Col II expression is abun-
dantly expressed within discrete nodules in wild-type cultures,
with weaker staining evident in the condensing mesenchyme sur-
rounding the nodules. (b) In transgenic cultures Col II is weakly
expressed within precartilaginous condensations, and has a more
widespread distribution. (c, e, and g) In wild-type cultures, N-cad,
Gli-1, and Col I are found predominantly in perinodular regions in
condensing mesenchymal cells with less expression in the core of
the nodules. (d, f, and h) In transgenic cultures, N-cad, Gli-1, and
Col I are expressed throughout the cultures in precartilaginous
condensations in a pattern similar to that of Col II. Bar, 1 mm. (i)
Comparison of Col II expression in wild-type and transgenic hind
limb buds indicates that Col II expression in wild-type and trans-
genic animals is similar at E11.5. At a later stage of hind limb de-
velopment (E14.5) that is accompanied by extensive extracellular
matrix deposition, Col II expression increases in wild-type limb
buds and decreases in transgenic limb buds. (j) Examination of
Col I expression in wild-type and transgenic hind limbs shows that
Col I expression is elevated in transgenic hind limb buds in com-
parison to wild-type hind limb buds at E13.5. Blots were re-
probed with an 18S rRNA to control for differences in loading
and transfer.The Journal of Cell Biology, Volume 148, 2000 684
transgene-expressing cells, whereas a loss of RARa activ-
ity induced cartilage formation. To further delineate the
role of BMP-2 and RARa in cartilage formation, we used
an approach that involves incubation of wild-type cultures
with AGN 194301 or BMP-2 for different periods of time
during culturing. To accomplish this, BMP-2 or AGN-
194301 were added to cultures for the first 2 or 3 d then re-
moved, or were added after 2 or 3 d of culturing. BMP-2 is
equally effective at stimulating cartilage formation when
present during the entire culture period or only after 2–3 d
after culture initiation (Fig. 5, d–f). Conversely, addition
of BMP-2 for the first 2 to 3 d of culture caused an increase
in nodule number but this increase was not as dramatic as
that observed upon adding BMP-2 later (i.e., after 2 or 3
d), and was not sustained. The size of the nodules was also
noticeably increased in cultures that were either continu-
ously exposed to BMP-2 (Fig. 5 d) or treated after 2 or 3 d
of culture initiation (Fig. 5, e and f). These large nodules
radiate towards the outside of the culture and are, in part,
a consequence of the recruitment of proliferating uncom-
mitted cells present in the periphery of the culture, into
the nodules (Duprez et al., 1996b). Hence, the conse-
quences of BMP-2 addition are much more pronounced in
cultures treated at later stages of culture and likely reflect
the ability of BMP-2 to enhance commitment of mesen-
chymal cells to the chondrocytic lineage with subsequent
recruitment into nodules.
In contrast to BMP-2, the response to AGN 194301 was
more pronounced when it was present early in the culture
period. When 1 mM AGN 194301 was added to cultures
for only the first 2 or 3 d, then removed, more cartilage
nodules were formed compared with untreated cultures
(Fig. 5, g–i) or to cultures exposed for longer periods of
time but untreated for the first 2 or 3 d (Fig. 5, k and l). In-
terestingly, the increase in nodule number caused by early
treatment of the antagonist was maintained even after six
or more days of its removal and was comparable to the in-
crease in nodule number observed with continuous treat-
ment (Fig. 5, h–j). Thus, AGN 194301 caused an increase
in nodule formation, however the nodules were z51%
smaller when compared with control cultures, but were
z22% larger in cultures receiving antagonist at later cul-
ture times. When BMP-2 and AGN 194301 were added to-
gether to wild-type cultures for 8 d at a concentration of 10
ng/ml and 1 mM, respectively, there was a z100% increase
in nodule number compared with untreated controls (Fig.
5 m). BMP-2 addition alone to cultures initiated from the
same limb buds caused a z45% increase, whereas AGN
Figure 3. Transgene-expressing cells condense but do not differentiate into chondroblasts in response to BMP-2. (a) Cartilage nodule
formation in BMP-2–treated and untreated, wild-type and transgenic cultures. Addition of BMP-2 (10 ng/ml) stimulates cartilage nod-
ule formation in all cultures in comparison to untreated cultures, with the exception of day 2 transgenic hind limb cultures. Within all
treatment groups there are fewer cartilage nodules in the transgenic cultures as compared with the corresponding wild-type culture. (b
and c) Wild-type cultures treated with BMP-2 were stained with alcian blue at days 2 and 4. In response to BMP-2, there is a noticeable
increase in nodule number and in nodule size (compare to Fig. 1, a–b). (d) Higher magnification of day 4 wild-type cultures treated with
BMP-2. (e–f) Transgenic cultures treated with BMP-2 were stained with magenta-gal at days 2 and 4 followed by alcian blue staining. In
response to BMP-2 there is an increase in nodule number and in nodule size. BMP-2 treatment also enhanced the formation and expan-
sion of transgene-expressing precartilaginous condensations. (g) Higher magnification of day 4 transgenic cultures treated with BMP-2.
BMP-2 stimulates condensation of transgene-expressing cells, however, similar to that observed in untreated cultures (Fig. 1 f), trans-
gene-expressing cells are mostly excluded from the nodules. (h and j) Analysis of Col II expression in wild-type and transgenic day 4 cul-
tures, respectively, with whole mount in situ hybridization. In wild-type cultures Col II is abundantly expressed within cartilage nodules,
whereas expression is much weaker and less distinct in transgenic cultures. (i) Addition of BMP-2 to wild-type cultures increases the
number of cartilage nodules that abundantly express Col II. (k) In transgenic cultures, treatment with BMP-2 results in more extensive
Col II expression, with most of the increase in expression present in weaker staining precartilaginous condensations. A few regions ex-
hibit higher levels of expression consistent with nodule formation. Bars: (b, c, e, and f) 1 mm; (d and g) 0.2 mm; (h–k) 0.5 mm.Weston et al. BMP and RA Signaling in Chondroblast Differentiation 685
194301 treatment caused an increase of z60% (Fig. 5 m).
In contrast to antagonist-treated cultures, BMP-2 treat-
ment increased nodule size by approximately eightfold
over that of untreated cultures. In accordance with these
results, an increase in Col II expression was observed in re-
sponse to treatment of cultures with either BMP-2 or
AGN 194301 for 4 d (Fig. 5 n), with the effect of BMP-2
being more pronounced. In addition, Col I expression was
decreased in BMP-2– and AGN 194301–treated cultures in
comparison to untreated cultures, albeit to a greater ex-
tent in AGN 194301–treated cultures. Together, these re-
sults suggest that the antagonist was operating to stimulate
chondroblast differentiation.
To further define the mechanism whereby cartilage for-
mation is enhanced by the antagonist, the ability of the
AGN 194301 to stimulate Col II expression in wild-type
cultures was assayed 24 h after culture initiation. There
was little to no detectable expression of Col II in untreated
cultures this early in the culture period (Fig. 5 o). Addition
of the antagonist, however, was sufficient to induce in-
tense Col II expression suggesting the presence of chon-
droblasts (Fig. 5 q). In cultures treated with BMP-2, Col II
expression induced after 24 h was weak in comparison to
the antagonist-treated cultures, but was localized to dis-
tinct regions indicative of precartilaginous condensations
(Fig. 5 p). Together, these results suggest that although
loss of RAR activity and the presence of a BMP signal
augment cartilage formation, they appear to do so through
distinct mechanisms.
Cartilage Formation Is Rescued in Noggin-treated 
Cultures by Addition of an RARa Antagonist
Previous experiments showed that the antagonist was able
to stimulate chondroblast differentiation before that ob-
served with BMP treatment. To further address the re-
quirement for BMPs in chondrogenesis, we treated wild-type
limb mesenchyme cultures with Noggin, a secreted inhibi-
tor of BMP-2, and -4. Addition of 10 ng/ml Noggin to wild-
type cultures dramatically reduced cartilage nodule forma-
tion by z84% in comparison to untreated controls (Fig. 6,
a, b, and d). In an attempt to define the chondrogenic
stage affected by Noggin, cultures treated with Noggin
were examined for the expression of Col II and Col IIA, an
alternatively spliced form of Col II expressed in prechon-
drogenic cells (Sandell et al., 1991, 1994). In limb bud-
derived cultures Col IIA is expressed in the condensing
mesenchyme surrounding cartilaginous nodules and in pre-
cartilaginous condensations (Fig. 6, e and f). If Noggin de-
lays or inhibits chondroblast differentiation but does not
affect condensation, then the decrease in Col II–express-
ing nodules should be accounted for by Col IIA–express-
ing condensations. In contrast, however, comparison of ex-
pression of these two genes by in situ hybridization in
Noggin-treated cultures indicates there are no additional
condensations present (Fig. 6, e and f). Hence, Noggin ap-
pears to interfere with formation of precartilaginous con-
densations.
Earlier experiments in which addition of BMP-2 was un-
able to rescue cartilage in transgene-expressing cultures
coupled with the accelerated appearance of Col II–expres-
sing cells in antagonist-treated cultures suggests that loss
of RAR activity alone is sufficient to initiate the chondro-
genic differentiation program. To test this, Noggin-treated
cultures were exposed to the RAR antagonist. The addi-
tion of 1 mM AGN 194301 to Noggin-treated cultures,
stimulated cartilage nodule formation such that these cul-
tures resembled untreated cultures (Fig. 6, a, c, and d). In
contrast, addition of 10 or 20 nM all trans-RA further di-
minished nodule formation in Noggin-treated cultures
(data not shown). These results indicate that suppression
of RAR-mediated signaling not only stimulates expres-
sion of the chondrogenic phenotype, but can do so inde-
pendently of a BMP signal.
Discussion
The appropriate timing of chondroblast differentiation
is critical to proper formation of the appendicular skele-
ton. We have demonstrated that the status of RAR ac-
tivity determines when prechondrogenic cells in the
limb differentiate into chondroblasts. Continued expres-
sion of an RARa transgene maintains the prechon-
drogenic phenotype of condensed mesenchyme and
prevents their differentiation, whereas cessation of RAR-
mediated signaling induces chondroblast differentiation.
The importance of RARs in this process is further ex-
emplified by the observations that addition of BMP-2 or
-4 is not sufficient to initiate chondroblast differentia-
tion of transgene-expressing cells. Furthermore, addition
of an RAR antagonist results in cartilage formation in
the presence of Noggin, a BMP inhibitor. Thus, BMP-
and RAR-mediated signals have distinct roles that to-
gether coordinate the growth and differentiation of skel-
etal progenitors.
Figure 4. The RARa-selective antagonist AGN 194301 inhibits
stimulation of an RARE-reporter gene by all-trans RA in a dose-
dependent manner. Low concentrations of AGN 194301 selec-
tively inhibit RARa-mediated transactivation of the reporter
gene in cultures cotransfected with an RARa expression con-
struct. At higher concentrations of AGN 194301, the compound
exhibits less selectivity, in that there is also decreased reporter
gene activity in cultures cotransfected with RARb or RARg ex-
pression plasmids.The Journal of Cell Biology, Volume 148, 2000 686
Figure 5. BMP-2 and AGN 194301 stimulate chondrogenesis at different stages of the chondrogenic sequence. (a) Untreated wild-type
cultures were stained with alcian blue on day 8. (b and c) Wild-type cultures were treated with BMP-2 (10 ng/ml) for the first 2 and 3 d
of culture, respectively, and stained with alcian blue on day 8. This treatment regiment results in a small increase in nodule number. (d)
Wild-type cultures were treated continuously with BMP-2 (10 ng/ml) and stained with alcian blue on day 8. (e and f) Wild-type cultures
were treated after 2 or 3 d, respectively, and stained with alcian blue on day 8. These cultures resemble cultures that were treated con-
tinuously with BMP-2, in that there is a substantial increase in both nodule number and size. (g) Untreated wild-type cultures were
stained with alcian blue on day 8. (h and i) Wild-type cultures were treated with AGN 194301 (1 mM) for the first 2 and 3 d of culture,
respectively, and stained with alcian blue on day 8. These cultures resemble cultures treated continuously with AGN 194301 (j) in that
there are significantly more nodules than in control cultures. (j) Wild-type cultures were treated continuously with AGN 194301 and
stained with alcian blue on day 8. (k and l) Wild-type cultures were treated with AGN 194301 after two or three days respectively and
stained with alcian blue at day 8. There are fewer cartilage nodules compared with cultures treated continuously, but they are larger.
Shaded boxes above the figure panels represent the days cells were treated during the 8-d culture period. (m) Quantification of cartilage
nodule formation in response to BMP-2 and AGN 194301. In response to BMP-2, or AGN 194301 alone, there is a significant increase in
the number of cartilage nodules over control cultures. Simultaneous addition of BMP-2 and AGN 194301 leads to a further increase in
the number of nodules that form. (n) Analysis of Col I and Col II expression in day 4 wild-type cultures treated with AGN 194301 (1 mM)
or BMP-2 (10 ng/ml) compared with untreated controls. Both treatments were found to increase Col II expression and to decrease Col I
expression to varying degrees. The blots were rehybridized with an 18S rRNA probe to control for differences in RNA abundance. (o–q)
Analysis of Col II mRNA expression in wild-type cultures after a 24-h treatment period. (o) Col II expression is not detectable in un-
treated cultures. (p) In BMP-2 (10 ng/ml)–treated cultures, Col II is weakly expressed. (q) In cultures treated with AGN 194301 (1 mM)
there is much more extensive Col II expression than in control or BMP-2–treated cultures, with a few distinct regions of more intense
Col II expression (arrowheads) being present that are not observed in control or BMP-2–treated cultures. Bars: (a–l) 1 mm; (n–p) 0.5.Weston et al. BMP and RA Signaling in Chondroblast Differentiation 687
Function of RARs in Skeletal Development
Manipulation of the RA signaling cascade during skeletal
morphogenesis leads to a number of characteristic malfor-
mations. The developing skeleton is especially sensitive to
RA, as embryos exposed to RA between E10.5 and E14
present with a number of limb malformations, including
skeletal elements that are missing, fused, thickened, or re-
duced in size (Kochhar, 1973; Kwasigroch and Kochhar,
1980). While RARa and g single null mutants do not have
appendicular defects (Li et al., 1993; Lohnes et al., 1993;
Lufkin et al., 1993; Subbarayan et al., 1997), compound
mutant mice exhibit a number of defects (Lohnes et al.,
1994). Overexpression of a weak constitutively active
RARa in the limbs also contributes to the development of
skeletal defects, with severity being proportional to the
level of transgene expression (Cash et al., 1997). These
manipulations of either RA or its receptors modify forma-
tion of the skeleton by affecting chondrogenesis, however,
the molecular and cellular basis of these effects is not well
understood.
To better understand the function of the RARs in chon-
drogenesis the aforementioned transgenic mice were fur-
ther investigated. Transgene-expressing cells have a pre-
chondrogenic phenotype, demonstrated by expression of
N-cad, Gli-1, Col I, and weak Col II, a pattern of expres-
sion that is seen in precartilaginous condensations and the
perichondrium. The normal expression pattern of RARa
in the developing limb is consistent with its absence being
essential for the transition from a chondroprogenitor to a
chondroblast. RARa is expressed in the prechondrogenic
condensations, the perichondrium, and in the interdigital
region, but is downregulated in newly formed cartilagi-
nous elements in vivo (Dolle et al., 1989) and cartilages in
vitro (Cash et al., 1997). Moreover, the abrogation of
RARa through the use of a specific antagonist stimulates
cartilage formation in vitro. Taken together, these results
suggest that a loss of RARa activity regulates the expres-
sion of the chondroblastic phenotype, and hence is a
pivotal step in coordinating the timing of chondroblast
differentiation. Downregulation of RAR activity during
chondroblast differentiation is accompanied by an in-
crease in the expression of RA 4-hydroxylase (referred to
as P450RA) in precartilaginous condensations (de Roos
et al., 1999), which catalyzes 4-hydroxylation of RA
(White et al., 1996, 1997). In this manner, downregulation
of RARa combined with increased degradation of RA
Figure 6. Rescue of cartilage formation in Noggin-treated cul-
tures by addition of AGN 194301. (a) Wild-type cultures were
stained with alcian blue on day 6. (b) Wild-type cultures treated
with Noggin (10 ng/ml) were stained with alcian blue on day 6. In
comparison to control cultures, only a few weakly stained nod-
ules are evident and these are present within the center of the
culture where cell density is highest. (c) Wild-type cultures were
treated with 10 ng/ml Noggin and 1 mM AGN 194301. When Nog-
gin and AGN 194301 are added together, there is no apparent de-
crease in nodule formation in comparison to untreated cultures.
Similar to that observed in control cultures, nodules are distrib-
uted throughout the culture. (d) Quantification of cartilage nod-
ule formation in response to Noggin and AGN 194301. Treatment
of Noggin alone dramatically reduces the number of cartilage
nodules to z10% of that of control cultures. Addition of
AGN  194301 to Noggin-treated cultures rescues cartilage forma-
tion and leads to an increase in cartilage nodule formation com-
parable to that of control cultures. (e and f) Analysis of Col IIA
and Col II expression in Noggin-treated cultures, respectively, re-
veals a comparable number of Col IIA–expressing aggregates
and  Col II–expressing nodules. Bar, 1 mm.The Journal of Cell Biology, Volume 148, 2000 688
Figure 7. Model for the role of the BMP- and RA-signaling pathways in limb skeletal development. Mesenchymal cells become com-
mitted to a chondrogenic cell fate by signals that are not well defined. Stabilization and expansion of this committed cell population ap-
pears to require the action of the BMPs. The availability of BMPs along with RA is important for the maintenance of prechondrogenic
cell populations present in precartilaginous condensations and the perichondrium. Loss of RAR activity induces skeletal progenitor dif-
ferentiation and emergence of the chondroblast phenotype. In the absence of BMP signals, chondroprogenitors that continue RARa
expression loose their prechondrogenic phenotype. Genes within boxes represent their expression in those cell types in vivo.
would result in an even greater decrease in RAR activity
and the subsequent stimulation of chondroblast differenti-
ation.
RARa has an important role in chondroblast differenti-
ation, however, the involvement of RARg cannot be pre-
cluded. In contrast to RARa, RARg expression is upregu-
lated during chondroblast differentiation (Cash et al.,
1997; Dolle et al., 1989). RARa and RARg null mutants
do not exhibit appendicular skeletal defects, whereas limb
skeletal abnormalities are observed in RARa2/2 g2/2
embryos (Lohnes et al., 1994). Thus, under certain circum-
stances RARg is able to, in part, compensate for the ab-
sence of RARa and vice versa, the skeletal defects in the
RARa/g null mutants can be rescued, for the most part by,
a single allele of RARa2 (Lohnes et al., 1994).
BMP and RAR Signaling in Limb Skeletal Development
RARa and RARg are expressed in condensed mesen-
chyme and perichondrial cells, which are both sites of ac-
tion of BMP-2 and BMP-2/4, respectively (Jones et al.,
1991; Duprez et al., 1996a; Rosen et al., 1996; Macias et al.,
1997). Support for the importance of BMP signaling in car-
tilage formation comes from studies using dominant-nega-
tive or constitutively active BMP type IB receptors in vitro
and in vivo to inhibit and stimulate chondrogenesis, re-
spectively (Kawakami et al., 1996; Zou et al., 1997). Fur-
thermore, loss or gain of function studies with Noggin, an
inhibitor of BMP-2 and -4 (Zimmerman et al., 1996), have
shown that BMP-2 and -4 are important in skeletal devel-
opment and that regulation of BMP signaling is required
for delineation of the various skeletal elements (Brunet
et al., 1998; Capdevila and Johnson, 1998; Pizette and
Niswander, 1999). BMP signaling may function in the
specification of mesenchyme to the chondrocytic lineage,
expansion of prechondrogenic cell populations and/or
chondroblast differentiation. Transgene expression inhib-
its chondroblast differentiation, even in the presence of
BMP-2 or -4. Both BMP-2 and -4 enhance the expression
of the prechondrogenic phenotype by stimulating the con-
densation of transgene-expressing cells as confirmed by
magenta-gal staining and by in situ hybridization with
probes for Col II (Fig. 3, j and k), N-cad, Gli-1 and Col I
(data not shown). This shows that BMPs are able to stimu-
late expansion of prechondrogenic cell populations, but,
are unable to circumvent the requirement for abrogation
of RAR activity in chondroblast differentiation.
As described herein, exogenous added Noggin inhibits
cartilage formation of limb mesenchyme in culture. The
decrease in nodule formation observed in response to
Noggin appears to be due to reduced formation of precar-
tilaginous condensations. While Noggin may not bind to
all BMP/GDF family members it appears to interact with
those BMP species important in the early stages of skeletal
development within the limb. These results suggest that
BMPs have an important function early on in chondro-
genesis at the condensation stage or preceding it. Manipu-
lation of the retinoid signaling pathway is important in
regulating chondroblast differentiation. Premature chon-
droblast differentiation is induced by the antagonist after
only 24 h of culture, before that observed with BMP addi-
tion. Hence, both BMP and retinoid signaling pathways
make fundamental contributions to skeletal development.
BMP signaling is required early in skeletal development
for the establishment and possibly maintenance of cells in
precartilaginous condensations, while retinoid signaling
acts later to control their differentiation.
The proposed role for RAR-signaling in chondroblast
differentiation can account for the skeletal defects ob-
served upon their manipulation in animals. Loss of RAR
signaling is expected to cause precocious differentiation of
skeletal progenitors and lead to a reduction in size or com-
plete absence of skeletal elements as observed in some
compound RAR and RAR/RXR mutant animals. If dif-
ferentiation occurs before prechondrogenic populations
reach a critical size, then the resultant cartilage elements
would not form or would be reduced in size (Hall and Mi-
yake, 1992). This is also consistent with the smaller, hypo-
plastic nodules observed herein in limb mesenchyme
cultures in response to abrogation of RAR signaling. Con-
versely, inappropriate activation of the RAR signaling
pathway would inhibit cartilage formation by prevent-Weston et al. BMP and RA Signaling in Chondroblast Differentiation 689
ing chondroblast differentiation, thereby resulting in a loss
or reduction in the size of the skeletal elements as ob-
served in RA teratogenicity or in transgenic animals over-
expressing a weak constitutively active RARa.
Diminution of RAR activity was sufficient to stimulate
cartilage formation in the presence of Noggin. Noggin
blocks cartilage formation at the condensation stage or
earlier, suggesting that attenuation of retinoid signaling
not only stimulates chondroblast differentiation, but may
also be sufficient to initiate the chondrogenic sequence in
a BMP-independent manner. This possibility is supported
by the presence of ectopic cartilages at a number of sites in
RARa2/2 g2/2 mice. In these animals cartilages appear
in the meninges, peritoneum, diaphragm, and at the base
of the semi-lunar cusps in the heart (Lohnes et al., 1994;
Mendelsohn et al., 1994). In addition, loss of RAR activity
can lead to the formation of interdigital cartilages as ob-
served in some RARa/g compound knockouts (Lohnes
et al., 1994) and by application of an RAR antagonist to
the interdigital region (Rodriquez-Leon et al., 1999).
Hence, this suggests that, in some instances, cartilage for-
mation can proceed, through a BMP-independent mecha-
nism.
A proposed model for the action of BMP and RAR sig-
naling in early limb skeletogenesis, those stages involved
with establishment of chondrogenic elements, is illustrated
in Fig. 7. During limb outgrowth chondroprogenitors do
not spontaneously differentiate into chondroblasts. In-
stead, their differentiation is temporally regulated during
limb bud outgrowth, such that proximal cells within the
limb bud differentiate before distal cells. Similarly, apposi-
tional growth of the cartilages is mediated by the spa-
tiotemporal differentiation of perichondrial cells to chon-
drocytes (Bairati et al., 1996). RAR activity in conjunction
with a BMP signal in prechondrogenic condensations and
the perichondrium in vivo are required for the expression
of the prechondrogenic phenotype. The maintenance of a
population of prechondrogenic cells such as those in the
perichondrium may therefore be attributed to the contin-
ued activity of these gene products in this region (von
Schroeder and Heersche, 1998; Koyama et al., 1999). Loss
of RAR activity in limb precartilaginous condensations or
perichondrial cells leads to their differentiation, contribut-
ing to longitudinal and appositional cartilage growth, re-
spectively.
RAR and BMP signaling may act in a similar manner to
coordinate other developmental processes. During heart
formation BMP-2 and -4 appear to be important in speci-
fying ventricular cardiomyocytes (Schultheiss et al., 1997),
whereas the RARs regulate the differentiation of this pop-
ulation of cells. Loss of RAR activity through inactivation
of RARa, along with either RXRa, RXRb, or the activa-
tion function 2 of RXRa causes precocious differentiation
of ventricular myocytes leading to a hypoplastic ventricu-
lum (Kastner et al., 1997; Mascrez et al., 1998). Thus, an
important function for the loss of a retinoid-mediated sig-
nal in controlling the timing of progenitor cell differentia-
tion is emerging in various morphogenetic processes.
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